Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Prostatic Neoplasms 1Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer 1Ovarian Neoplasms 1Melanoma 1Locally Advanced Colorectal Cancer 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1

Interventions

Oxaliplatin 64pembrolizumab 48Fluorouracil 44Capecitabine 38Nivolumab 33Leucovorin 32Paclitaxel 28Trastuzumab 19Docetaxel 18Cisplatin 18S 1 (combination) 16Bevacizumab 15Ramucirumab 13Irinotecan 13Drug Therapy 13tislelizumab 12Cyclophosphamide 12fludarabine 10Carboplatin 10Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 8sintilimab 8Specimen Handling 8Biopsy 8atezolizumab 7Surgical Procedures, Operative 7Gemcitabine 7zolbetuximab 6durvalumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × SHR-1701 × 1 year × Clear all
NCT07311408 2025-12-31

SHR-2554

China Medical University, China

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Stomach Neoplasms

NCT07102901 2025-09-10

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
351 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡